DCM
TVRD

Driehaus Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Driehaus Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-446
Closed -$247K – 620
2017
Q2 		$247K Sell
446
-687
-61% -$436K 0.01% 487
2017
Q1 		$750K Buy
+1,133
New +$605K 0.03% 398

Other funds holding TVRD

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Driehaus Capital Management's TVRD Position: Q3 2017 in Review

Driehaus Capital Management sold out of Tvardi Therapeutics (TVRD) in Q3 2017, closing a stake of 446 shares — an estimated $247K sold.

Driehaus Capital Management first reported a position in TVRD in Q1 2017 and held it in 2 quarters. The position peaked at $750K in Q1 2017. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2017.

  • Driehaus Capital Management reported no remaining Tvardi Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Driehaus Capital Management sold 446 Tvardi Therapeutics shares in Q3 2017, an estimated $247K.
  • Driehaus Capital Management first reported a position in Tvardi Therapeutics in Q1 2017 and held it in 2 quarters.
  • Driehaus Capital Management's Tvardi Therapeutics position peaked at $750K in Q1 2017.
  • 121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2017.

Based on Driehaus Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.